Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson's disease (PD)

被引：0
|
作者：
Afshari, Z.
Nguyen, N.
Afshari, M.
机构：
来源：
MOVEMENT DISORDERS | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
817
引用
收藏
页码：S368 / S368
页数：1
相关论文
共 50 条
  • [31] Effect of Patient Characteristics on Motor Function in Response to 35-50 mg of Inhaled Levodopa (CVT-301) in Patients with Parkinson's Disease: Results from a Phase 2b Study
    Lewitt, Peter
    Freed, Martin
    Leinonen, Mika
    Sedkov, Alexander
    Murck, Harald
    NEUROLOGY, 2016, 86
  • [32] Effect of patient characteristics on motor function in response to 35-50 mg of inhaled levodopa (CVT-301) in patients with Parkinson's disease: Results from a phase 2b study
    LeWitt, P. A.
    Freed, M. I.
    Leinonen, M.
    Sedkov, A.
    Murck, H.
    MOVEMENT DISORDERS, 2016, 31 : S660 - S660
  • [33] High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials
    Zeya Yan
    Wei Wang
    Xinyu Tao
    Wei Cheng
    Gang Zuo
    Zhouqing Chen
    Zhong Wang
    Gang Chen
    Neurological Sciences, 2022, 43 : 6233 - 6241
  • [34] Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes
    Thach, Andrew
    Zichlin, Miriam L.
    Kirson, Noam
    Yang, Karen
    Gaburo, Katherine
    Pappert, Eric
    Mehta, Darshan
    Williams, G. Rhys
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (04) : 285 - 295
  • [35] High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials
    Yan, Zeya
    Wang, Wei
    Tao, Xinyu
    Cheng, Wei
    Zuo, Gang
    Chen, Zhouqing
    Wang, Zhong
    Chen, Gang
    NEUROLOGICAL SCIENCES, 2022, 43 (11) : 6233 - 6241
  • [36] Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for "OFF" Episodes in Parkinson's Disease
    Thach, A.
    Zichlin, M.
    Kirson, N.
    Yang, K.
    Gaburo, K.
    Pappert, E.
    Mehta, D.
    Williams, G.
    MOVEMENT DISORDERS, 2021, 36 : S197 - S197
  • [37] A Preliminary Report on the Clinical Profile of People with Parkinson's disease (PD) at an Outpatient Clinic in Malawi
    Gwedela, M.
    Phiri, T.
    MOVEMENT DISORDERS, 2024, 39 : S375 - S375
  • [38] A novel levodopa dry powder inhaler for treatment of off periods in Parkinson's disease patients
    Luinstra, M.
    Grasmeijer, F.
    Hagedoorn, P.
    Frijlink, H. W.
    de Boer, A. H.
    MOVEMENT DISORDERS, 2015, 30 : S427 - S427
  • [39] HVA CSF levels in Parkinson's disease patients after levodopa challenge: A new diagnostic tool?
    Stefani, A.
    Galati, S.
    Liguori, C.
    Olivola, E.
    Pierantozzi, M.
    MOVEMENT DISORDERS, 2015, 30 : S129 - S129
  • [40] CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) over 12 weeks
    Ellenbogen, A.
    Corbin, A.
    Zhao, P.
    Kegler-Ebo, D.
    Roberts, H.
    MOVEMENT DISORDERS, 2020, 35 : S393 - S393
12345